L2777
Lisinopril
ACE Inhibitor
Synonym(s):
(S)-Nα-(1-Carboxy-3-phenylpropyl)-Lys-Pro
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
Quality Level
General description
Lisinopril is a nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor. It is used in the treatment of heart failure and hypertension. Lisinopril is an antihypertensive and anticongestive agent, like other members of its family. It is water-soluble and possesses weak chelating properties.
Application
Lisinopril has been used as an angiotensin-converting enzyme (ACE) inhibitor:
- in combination with spironolactone, to study their effects on cardiac and skeletal muscles in the Duchenne muscular dystrophy (DMD) mice model
- standard in in vitro ACE inhibitory assay
- as a negative control in ACE enzymatic assay
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Repr. 1A - STOT RE 2
Target Organs
Kidney
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
ACE Inhibitory Peptides from Bellamya bengalensis Protein Hydrolysates: In Vitro and In Silico Molecular Assessment
Processes, 9(8), 1316-1316 (2021)
Prednisolone Attenuates Improvement of Cardiac and Skeletal Contractile Function and Histopathology by Lisinopril and Spironolactone in the mdx Mouse Model of Duchenne Muscular Dystrophy
PLoS ONE (2014)
Clinical science (London, England : 1979), 95(6), 709-717 (1998-12-01)
1. Our objective was to compare the effect of a long-acting calcium antagonist (nisoldipine) compared with an angiotensin-converting enzyme inhibitor (lisinopril) on the non-neurogenic regulation of the microvascular blood flow in hypertensive Type I diabetes patients with diabetic nephropathy.2. We
Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics.
Cardiovascular Drug Reviews (1990)
Clinical science (London, England : 1979), 96(6), 669-675 (1999-05-21)
In the kidney and colon 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) inactivates cortisol to cortisone, thereby protecting the non-selective mineralocorticoid receptor from cortisol. Deficiency of 11beta-HSD2 results in cortisol-mediated sodium retention and hypertension, suggesting that the physiological regulation of 11beta-HSD2 in
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service